TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The cryoICE™ CryoAnalgesia Study For Pain Management in Post thoRacic Procedures Via intercOSTal Cryoanalgesia (FROST)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 - 85 years male or female~* Patients undergoing unilateral thoracotomy cardiac procedures (with the exception of Aortic Aneurysm repair as sole treatment)~* Acceptable surgical candidate, including use of general anesthesia~* Willing and able to provide written informed consent~* Willing and able to return for scheduled follow-up visits~Exclusion Criteria:~* Cardiac valve surgical procedure via conventional full sternotomy~* Procedures that require a posterolateral thoracotomy~* Current pregnancy~* Current use of prescription opioids~* FEV1 \< 40% predicted~* Documented myocardial infarction within 30 days of signing Informed Consent Form (ICF)~* Documented psychiatric disease~* Documented chronic pain syndrome~* Documented history of substance abuse~* Patient currently enrolled in another research study that could directly affect results of either study~* Physical or mental condition that would interfere with patient's self-assessment of pain~* Disqualifying medical condition per investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Cryoanalgesia + Standard of Care (SOC) (Type: EXPERIMENTAL): Cryoanalgesia in Conjunction with Standard of Care. Up to 5 sessions of cryoanalgesia for 120 seconds per session.
- Standard of Care (Type: ACTIVE_COMPARATOR): Institutional SOC for pain management will be followed. The use of local post-operative pain management techniques (i.e., intercostal, peri-vertebral, or any other acceptable method) is permitted for both treatment groups up to 24 hours post-operatively according to institutional standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed colorectal adenocarcinoma;~* Availability of formalin-fixed paraffin embedded tumor block from primary and/or metastasis;~* BRAF V600E mutant status of primary colorectal cancer and/or related metastasis;~* Unresectable and measurable metastatic disease according to RECIST criteria;~* Male or female, aged \> 18 years and \< 75 years;~* ECOG PS \< 2 if aged \< 71 years;~* ECOG PS = 0 if aged 71-75 years;~* Life expectancy of more than 3 months;~* Adequate haematological function: ANC ≥ 1.5 x 10\^9/L; platelets ≥ 100 x 10\^9/L, Hb ≥ 9 g/dL;~* Adequate liver function: serum bilirubin ≤ 1.5 x ULN; alkaline phosphatase and transaminases ≤ 2.5 x ULN (in case of liver metastases ≤ 5 x ULN);~* Serum creatinine ≤ 1.5 x ULN;~* Previous adjuvant chemotherapy is allowed if more than 12 months have elapsed between the end of adjuvant therapy and first relapse;~* At least 6 weeks from prior extended radiotherapy and 4 weeks from surgery;~* Written informed consent to experimental treatment and molecular analyses.~Exclusion Criteria:~* Presence or history of CNS metastasis;~* Serious, non-healing wound, ulcer, or bone fracture;~* Evidence of bleeding diathesis or coagulopathy;~* Uncontrolled hypertension;~* Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (CVA) (≤6 months before treatment start), myocardial infarction (≤ 6 months before treatment start), unstable angina, NYHA ≥ grade 2 chronic heart failure (CHF), uncontrolled arrhythmia;~* Current or recent (within 10 days prior to study treatment start) ongoing treatment with anticoagulants for therapeutic purposes;~* Chronic, daily treatment with high-dose aspirin (\>325 mg/day);~* Symptomatic peripheral neuropathy ≥ 2 grade NCIC-CTG criteria;~* Active uncontrolled infections;~* Treatment with any investigational drug within 30 days prior to enrolment;~* Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of curatively treated basal and squamous cell carcinoma of the skin or in situ cancer of the cervix;~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start;~* Lack of physical integrity of the upper gastrointestinal tract or malabsorption syndrome;~* Fertile women (\< 2 years after last menstruation) and men of childbearing potential not willing to use effective means of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BRAF mutant mCRC (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Post-Exposure Sauna Treatment of Firefighters - A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are employed as an active fire responder by the Fire Department~* Are scheduled for a training fire exercise by the Fire Department in the next year~* Are currently a non-smoker (including cigarettes, cigars and e-cigarettes)~* Cannot have any contraindications to the core temp pill, which are:~  * weight less than 80 pounds~ * known or suspected obstructive disease of GI tract, including but not limited to diverticulitis and inflammatory bowel disease~ * exhibit or have a history of disorders or impairment of the gag reflex~ * have had a previous gastrointestinal surgery~ * have any diseases or disorders of the esophagus~ * will be undergoing Nuclear Magnetic Resonance (NMR) or MRI scanning less than 3 days after swallowing the sensor~ * have a low motility disorder of the gastrointestinal tract including but not limited to ileus~ * have a cardiac pacemaker or other implanted electromedical device~ * have a swallowing disorder~Exclusion Criteria:~* Are NOT employed as an active fire responder by the Fire Department~* Are NOT scheduled for a training fire exercise by the Fire Department in the next year~* Are currently a smoker (including cigarettes, cigars and e-cigarettes)~* Has one of the contraindications to the core temp pill

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- No additional rehabilitation (Type: NO_INTERVENTION): No additional rehabilitation will be done
- Sauna rehabilitation (Type: OTHER): An additional rehabilitation in a sauna will be done

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With PNH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be at least 18 years old (inclusive).~* Have LDH ≥1.5 x ULN at the screening visit.~* Have PNH diagnosis, confirmed by high sensitivity flow cytometry (granulocyte or monocyte clone \>10%).~* Have Hb less than the lower limit of normal (LLN) at the screening visit.~* Have ferritin greater than/equal to the LLN, or total iron binding capacity (TIBC) less than/equal to ULN at the screening visit, based on central laboratory reference ranges. If a subject is receiving iron supplements at screening, the Investigator must ensure that the subject's dose has been stable for 4 weeks prior to screening, and it must be maintained throughout the study. Subjects not receiving iron at screening must not start iron supplementation during the course of the study.~* Body mass index (BMI) ≤ 35 kg/m2 at the screening visit.~* Have a platelet count of \>50,000/mm3 at the screening visit.~* Have an absolute neutrophil count \>500/mm3 at the screening visit.~Exclusion Criteria:~* Treatment with any complement inhibitor (eg, eculizumab) within 3 months prior to screening.~* Hereditary complement deficiency.~* History of bone marrow transplantation.~* Concomitant use of any of the following medications is prohibited if not on a stable regimen for the time period indicated below prior to screening:~  * Erythropoietin or immunosuppressants for at least 8 weeks~ * Systemic corticosteroids for at least 4 weeks~ * Vitamin K antagonists (eg, warfarin) with a stable international normalized ratio (INR) for at least 4 weeks~ * Iron supplements, vitamin B12, or folic acid for at least 4 weeks~ * Low-molecular-weight heparin for at least 4 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (SOC) excluding complement inhibitors (Type: NO_INTERVENTION): None
- 1,080mg APL-2 administered subcutaneously twice weekly (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 5-17 years of age, has a diagnosis of Hemophilia A or B.~Exclusion Criteria:~* Muscle or joint bleed within 4 weeks of study.~* Pre-existing co-morbidities that would affect physical activity participation.~* Unable to cooperate with study protocol.~* Unable to speak, read, or understand English.

- Gender: MALE
- Minimum Age: 5 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Boys with Hemophilia (Type: None): Accelerometer use for 1 week.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Parecoxib on Morphine Patient-controlled Epidural Analgesia (PCEA) After Gynecologic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women scheduled for elective gynecological surgery under combined spinal-epidural anesthesia~Exclusion Criteria:~* contraindications for CSE placement~* known allergy, sensitivity, or contraindication to opioid and nonopioid analgesic drugs~* history of bleeding disorders, peptic ulceration, or anticoagulant use within the past month~* current pregnancy or breastfeeding~* history of known or suspected drug abuse~* unable to understand the use of pain assessment scales and the PCA device~* Patient with asthma or bronchospasm, requiring treatment with glucocorticoids~* poorly controlled hypertension or diabetes, a chronic or acute renal or hepatic disorder, or inflammatory bowel disease~* patients had taken antidepressants, narcotic analgesics, antihistamines, anxiolytics, hypnotics, sedatives, NSAIDs, or corticosteroids up to 24 h before receipt of the study medication

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: PLACEBO_COMPARATOR): Before incision, patients in controlled Group received NS
- parecoxib sodium (Type: EXPERIMENTAL): Before incision, parecoxib patients received 40mg of parecoxib IV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Omeprazole-Containing Products for Relief of Frequent Heartburn (MK-0764A-036)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females of reproductive potential must demonstrate a negative urine pregnancy test and agree to use an acceptable method of birth control~* Suffer from frequent heartburn~* Refrain from taking non-study medicine or treatment for heartburn for the duration of the study~* Be free of any clinically significant disease that requires a physician's care~* Read and understand English~Exclusion Criteria:~* Any significant medical condition which is a contraindication to the use of omeprazole or sodium bicarbonate~* Known hypersensitivity to the study drugs or any components~* Experiencing any of the following: trouble or pain with swallowing food, vomiting with blood, bloody or black stools~* Participation in another investigational study within 4 weeks prior to the screening visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Omeprazole 20 mg + Sodium Bicarbonate 1100 mg (Type: EXPERIMENTAL): Participants will receive omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg once a day for 4 days.
- Omeprazole 20 mg (Type: ACTIVE_COMPARATOR): Participants will receive omeprazole 20 mg once a day for 4 days, and then after a washout period, omeprazole 20 mg + sodium bicarbonate 1100 mg once a day for 4 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~1. Is aged 4 to 16 years, inclusive (Latin America) or 4 to 8 years, inclusive (Asia).~2. Are in good health at the time of entry into the study as determined by medical history, physical examination (including vital signs), and clinical judgment of the investigator.~Main Exclusion Criteria:~1. Febrile illness (body temperature ≥38°C) or moderate or severe acute illness or infection at the time of enrolment.~2. History or any illness that, in the opinion of the investigator, might interfere with the results of the study or pose an additional risk to the participant due to participation in the study.~3. Receipt of any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to Day 1 (Month 0) or planning to receive any vaccines within 28 days after Day 1 (Month 0).~4. Previous participation in any clinical study of a dengue candidate vaccine, or previous receipt of any dengue vaccines (investigational or licensed).

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- Tetravalent Dengue Vaccine (TDV) 0.5 mL (Type: EXPERIMENTAL): TDV 0.5 mL, subcutaneous (SC) injection, on Day 1 (Month 0) and Day 90 (Month 3).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with biopsy-proven Muscular Dystrophy of Duchenne or Becker~Exclusion Criteria:~* Contraindications to cardiovascular magnetic resonance imaging

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ACE inhibitor (Type: EXPERIMENTAL): ACE inhibitor (enalapril up to 20mg BID), in patients with preserved EF (LVEF grater than 50%) and with detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance, randomized to therapy or not.
- Control (Type: NO_INTERVENTION): Patients with preserved EF (LVEF grater than 50%) and with no detectable delayed enhancement (myocardial fibrosis) in cardiac magnetic resonance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemoembolization of the Liver With or Without Sunitinib Malate in Treating Patients With Liver Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed hepatocellular carcinoma or liver tumor responding to the Barcelona criteria~* Child-Pugh score of 5-6 (Class A)~* Tumor suitable for transarterial chemoembolization (one or more planned courses allowed)~* Tumor not suitable for surgical resection~* No extrahepatic metastases, including cerebral metastases~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Absolute neutrophil count ≥ 1.5 x 10\^9/L~* Platelet count ≥ 100 x 10\^9/L~* Hemoglobin ≥ 10 g/dL~* PT ≥ 50%~* Creatinine ≤ 120 μmol/L~* Bilirubin normal~* ALT/AST ≤ 3.5 times upper limit of normal (ULN)~* Alkaline phosphatases ≤ 4 times ULN~* Fibrinogen ≥ 1.5 g/L~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No portal vein thrombosis~* Able to comply with scheduled follow-up and management of toxicity~* No uncontrolled hypertension or requiring ≥ 2 classes of antihypertensive drugs~* No concomitant disease or uncontrolled severe disease~* No contraindications to the vascular occlusion procedure~* No prior or concurrent malignancy within the past 5 years, except adequately treated cone-biopsied carcinoma in situ of the cervix or basal cell carcinoma of the skin~* No psychiatric disability or social, family, or geographic reason for which the patient may not be followed regularly~PRIOR CONCURRENT THERAPY:~* At least 7 days since prior CYP3A4 inhibitors or inducers~* At least 3 months since prior radiofrequency ablation~* No prior chemotherapy~* No prior sunitinib, sorafenib, or any other inhibitors of angiogenesis~* No concurrent participation in another trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): placebo 3cps/days 4 weeks over 6 during 1 year
- Sunitinib (Type: EXPERIMENTAL): sunitinib (SUTENT®) 37,5 mg/d (3 cps of 12,5 mg) orally 4 weeks over 6 (4 weeks of treatment followed by 2 weeks without treatment) during 1 year

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Mood and Marriage Study (TOMMS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* One partner must receive a clinical diagnosis of major depressive disorder based upon our assessment~* Couples must be living together~* Either partner must report marital distress or tension~* Willing to take antidepressant medication and participate in weekly marital therapy and assessments~* The depressed partner cannot be involved in any other psychosocial treatment~* Score above 24 on the Mini Mental Status Exam~Exclusion Criteria:~* Both partners meet diagnostic criteria for major depressive disorder based on our evaluation~* Coexisting bipolar or psychotic disorder~* Evidence of a primary substance abuse or dependence disorder~* Current ECT treatment~* Evidence of active and severe domestic violence

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Medication management with a study doctor every other week.
- Combination (Type: EXPERIMENTAL): Medication management with a study doctor every other week plus weekly marital therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Continuous Infusion Ropivacaine Interscalene Blocks

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients will be eligible for inclusion in the study if they have a full-thickness rotator cuff tear that has been deemed reparable by preoperative MRI. They will be included in the study if they are medically stable to undergo the surgery and consent to involvement in the study.~Exclusion Criteria:~1. Prior surgery on the involved shoulder~2. Preoperative MRI suggesting that the rotator cuff tear is irreparable~3. Patients with known allergies to oxycodone, ropivacaine or a similar drug~4. Workman's compensation patients~5. Patients who do not fill out their visual analog scores or their medication diaries~6. Patients with labral or subscapularis tears requiring repair

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ropivacaine infusion (Type: ACTIVE_COMPARATOR): 270cc of Ropivacaine infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.
- Saline infusion (Type: PLACEBO_COMPARATOR): 270cc of Normal Saline infusion at 5cc per hour. All patients will receive a reservoir for their catheters containing 280cc of either ropivacaine or saline that will infuse at a rate of 6cc per hour. The reservoirs will be attached in the operating room at the completion of the rotator cuff repair. Patients will be randomized intraoperative to receive either the ropivacaine or the saline.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete